Aligos Therapeutics (ALGS) EV/EBITDA: History & Chart

Aligos Therapeutics, Inc.(ALGS)

Biotechnology · South San Francisco, CA

$5.40-0.14 (-2.53%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.

South San Francisco, CA

82 employees

www.aligos.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lawrence Blatt

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Aligos Therapeutics, Inc. (ALGS)	$33.42M	N/A	N/A	N/A	N/A
BeyondSpring Inc. (BYSI)vs ›	$32.32M	N/A	N/A	N/A	N/A
EUDA Health Holdings Limited (EUDA)vs ›	$32.31M	N/A	10986.66x	10986.66x	10986.66x
Baird Medical Investment Holdings Limited (BDMD)vs ›	$31.36M	N/A	N/A	N/A	N/A
Accuray Incorporated (ARAY)vs ›	$35.89M	N/A	25.79x	51.85x	38.84x
Context Therapeutics Inc. (CNTX)vs ›	$30.92M	N/A	N/A	N/A	N/A
DocGo Inc. (DCGO)vs ›	$36.05M	N/A	6.76x	19.14x	45.56x
CervoMed Inc. (CRVO)vs ›	$30.65M	N/A	0.36x	0.82x	0.82x
HeartBeam, Inc. (BEAT)vs ›	$36.31M	N/A	N/A	N/A	N/A
Elutia Inc (ELUT)vs ›	$36.32M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

Aligos Therapeutics, Inc. (ALGS)

$33.42M

N/A

BeyondSpring Inc. (BYSI)vs ›

$32.32M

N/A

EUDA Health Holdings Limited (EUDA)vs ›

$32.31M